Does tumoral 111In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing 90Y-ibritumomab radioimmunotherapy?-Reference-Cited by-同舟云学术

Does tumoral 111In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing 90Y-ibritumomab radioimmunotherapy?

Published:2014-08-12 Issue:12 Volume:24 Page:3191-3198
ISSN:0938-7994
Container-title:European Radiology
language:en
Short-container-title:Eur Radiol

Author:

Kaneko Koichiro,Choi Ilseung,Nakagawa Makoto,Shinozaki Kenji,Uike Naokuni

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00330-014-3378-4.pdf

Reference21 articles.

1. Stevens PL, Oluwole O, Reddy N (2012) Advances and application of radioimmunotherapy in non-Hodgkin lymphoma. Am J Blood Res 2:86–97

2. Fisher RI (2003) Overview of non-Hodgkin's lymphoma: biology, staging, and treatment. Semin Oncol 30:3–9

3. Witzig TE, White CA, Wiseman GA et al (1999) Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17:3793–3803

4. Wiseman GA, Gordon LI, Multani PS et al (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336–4342

5. Witzig TE, Flinn IW, Gordon LI et al (2002) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262–3269

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reduction of the hepatic radioactivity levels of [111In]In-DOTA–labeled antibodies via cleavage of a linkage metabolized in lysosomes;Nuclear Medicine and Biology;2024-05

2. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review;Current Cancer Therapy Reviews;2024-01

3. Predictive value of pre-treatment FDG PET in patients with non-Hodgkin lymphoma treated with radioimmunotherapy: a systematic review;Clinical and Translational Imaging;2019-06

4. Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?;European Radiology;2019-03-21

5. Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response;Critical Reviews in Oncology/Hematology;2016-11